TY - JOUR
T1 - Tumour uptake of 57-cobalt-bleomycin in patients with breast cancer
AU - Pace, L.
AU - D'Aiuto, G.
AU - Acampora, C.
AU - Oliviero, P.
AU - Botti, G.
AU - Tatangelo, F.
AU - Cerra, M.
AU - Salvatore, M.
PY - 1993
Y1 - 1993
N2 - 17 patients with breast carcinoma were studied with 57-cobalt-bleomycin scintigraphy. Scans showed increased tumour uptake in all patients. Results expressed as percentage of the injected dose (ID) normalised by the size of the tumour region (% ID/pixel) showed higher tumour uptake in patients with T3-T4 breast carcinomas (n = 5) than in patients with T1-T2 breast cancer (n = 12) (8.4 ± 0.55 × 10-3 vs. 5.25 ± 1.71 × 10-3 % ID/pixel, respectively, P <0.05). An inverse correlation between tumour uptake of 57-cobalt-bleomycin and progesterone receptor concentration was also found in all tumours tested (r = -0.60, P <0.05, n = 10) and was confirmed in the group of patients with T2 breast carcinomas (r = -0.89, P <0.05, n = 6). We conclude that a quantitative analysis of 57-cobalt-bleomycin uptake can give additional information suitable for the presurgical characterisation of a tumour.
AB - 17 patients with breast carcinoma were studied with 57-cobalt-bleomycin scintigraphy. Scans showed increased tumour uptake in all patients. Results expressed as percentage of the injected dose (ID) normalised by the size of the tumour region (% ID/pixel) showed higher tumour uptake in patients with T3-T4 breast carcinomas (n = 5) than in patients with T1-T2 breast cancer (n = 12) (8.4 ± 0.55 × 10-3 vs. 5.25 ± 1.71 × 10-3 % ID/pixel, respectively, P <0.05). An inverse correlation between tumour uptake of 57-cobalt-bleomycin and progesterone receptor concentration was also found in all tumours tested (r = -0.60, P <0.05, n = 10) and was confirmed in the group of patients with T2 breast carcinomas (r = -0.89, P <0.05, n = 6). We conclude that a quantitative analysis of 57-cobalt-bleomycin uptake can give additional information suitable for the presurgical characterisation of a tumour.
UR - http://www.scopus.com/inward/record.url?scp=0027201257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027201257&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(93)90173-D
DO - 10.1016/0959-8049(93)90173-D
M3 - Article
C2 - 7678495
AN - SCOPUS:0027201257
VL - 29
SP - 195
EP - 198
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 2
ER -